Transition to Human Phase 1b Trials: Nonclinical Studies of an Anti-METH mAb

过渡到人体 1b 期试验:抗 METH 单克隆抗体的非临床研究

基本信息

  • 批准号:
    8827127
  • 负责人:
  • 金额:
    $ 128.75万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-09-15 至 2017-06-30
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Methamphetamine (METH) abuse causes serious medical, social, and economic harm in the USA and the world. However, to date, no medications are approved to treat METH addiction. The primary goal of this translational project is to conduct safety studies of a new medicine for METH addiction, a novel anti- METH monoclonal antibody (mAb) called ch-mAb7F9, to support the initiation of a first clinical study in METH users. Results from a Phase 1a study of ch-mAb7F9 in non-METH-using healthy subjects indicate that the antibody is safe for administration in humans. Ch-mAb7F9 was created to selectively and quickly bind METH in the blood and prevent it from entering the brain and other tissues where it causes multiple health problems, including addiction. By so doing, anti-METH ch-mAb7F9 will transform the clinical treatment of addiction by providing the first medication that can reduce METH's reinforcing properties for prolonged periods of time. There is a high rate of recidivism associated with METH use. By using a long-acting antibody antagonist to provide around-the-clock protection from METH effects, patients will be much less vulnerable to relapse to METH use and thereby have significantly improved chances for recovery. Anti-drug mAb medications have major advantages for addiction therapy since steady-state concentrations and precise control of dosing are readily achievable even in immune compromised patients, and because they will not interact with other medicines. Furthermore, mAb medications are safe for most patient populations. For the research and testing program, ch-mAb7F9 will be tested in rats for safety in combination with high, binge-like doses of METH. Additionally, METH self-administration studies in rats will be performed to answer specific questions from the FDA concerning the motivation and ability of users to overcome the antibody's stimulant blocking effects. A highly experienced, trans disciplinary academic and industry team will accomplish the following Specific Aims: 1) complete essential regulatory work in preparation for a Phase 1b study; 2) manufacture ch-mAb7F9 for necessary nonclinical and future clinical studies, 3) conduct nonclinical testing to determine safety of the interaction between ch-mAb7F9 and METH in rats, and 4) test ch-mAb7F9 in METH self-administration studies to examine the motivational aspect of drug use. These studies are necessary to prepare for a Phase 1b study in METH users that will be crucial for identifying factors that determine optimal human dosing regimens and will allow for the effective design of future clinical studies where ch-mAb7F9 efficacy is the primary endpoint. The therapeutic vision is that this medication, which can be used to initiate and continue pharmacologic treatment, will be used in combination with high quality behavioral modification programs to dramatically improve patient outcomes.
 描述(申请人提供):甲基苯丙胺(冰毒)滥用在美国和世界造成严重的医疗、社会和经济危害。然而,到目前为止,还没有药物被批准用于治疗冰毒成瘾。这个翻译项目的主要目标是对一种治疗冰毒成瘾的新药进行安全性研究,一种名为ch-mAb7F9的新型抗冰毒单抗(MAb),以支持在冰毒使用者中启动第一项临床研究。在未使用冰毒的健康受试者中对ch-mAb7F9进行1a期研究的结果表明,该抗体在人体内注射是安全的。CH-mAb7F9是为了选择性地快速结合血液中的冰毒,并防止它进入大脑和其他组织,在那里它会导致包括成瘾在内的多种健康问题。通过这样做,抗冰毒单抗Ab7F9将改变成瘾的临床治疗,提供第一种可以长时间减少冰毒增强特性的药物。与使用冰毒相关的再犯罪率很高。通过使用长效抗体拮抗剂来提供24小时不受冰毒影响的保护,患者将不太容易再次使用冰毒,从而大大提高康复的机会。抗药物单抗药物在成瘾治疗中具有重大优势,因为即使在免疫功能低下的患者中,也很容易实现稳定的浓度和精确的剂量控制,而且因为它们不会与其他药物相互作用。此外,单抗药物对大多数患者群体是安全的。在这项研究和测试计划中,ch-mAb7F9将在大鼠身上进行安全性测试,与大剂量的大剂量冰毒相结合。此外,还将在大鼠身上进行冰毒自我给药研究,以回答FDA提出的有关使用者克服抗体刺激剂阻断效应的动机和能力的具体问题。一支经验丰富的跨学科学术和行业团队将实现以下具体目标:1)完成基本的监管工作,为1b期研究做准备;2)为必要的非临床和未来临床研究制造ch-mAb7F9;3)进行非临床测试,以确定ch-mAb7F9与冰毒相互作用的安全性;以及4)在冰毒自我给药研究中测试ch-mAb7F9,以检查药物使用的激励方面。这些研究对于准备在冰毒使用者中进行1b期研究是必要的,这对于确定决定最佳人体剂量方案的因素至关重要,并将允许有效设计未来的临床研究,其中ch-mAb7F9疗效是主要终点。治疗的愿景是,这种可用于启动和继续药物治疗的药物将与高质量的行为调整计划结合使用,以显著改善患者的结果。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

W BROOKS GENTRY其他文献

W BROOKS GENTRY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('W BROOKS GENTRY', 18)}}的其他基金

OUTLAST - A First Multiple-Dose Efficacy Study of IXT-m200, an anti-METH Monoclonal Antibody, in Patients with METH Use Disorder
OUTLAST - IXT-m200(一种抗冰毒单克隆抗体)在冰毒使用障碍患者中的​​首次多剂量疗效研究
  • 批准号:
    10686245
  • 财政年份:
    2021
  • 资助金额:
    $ 128.75万
  • 项目类别:
OUTLAST - A First Multiple-Dose Efficacy Study of IXT-m200, an anti-METH Monoclonal Antibody, in Patients with METH Use Disorder
OUTLAST - IXT-m200(一种抗冰毒单克隆抗体)在冰毒使用障碍患者中的​​首次多剂量疗效研究
  • 批准号:
    10399794
  • 财政年份:
    2021
  • 资助金额:
    $ 128.75万
  • 项目类别:
Meth-OD: A PHASE 2A STUDY OF IXT-M200 IN METHAMPHETAMINE OVERDOSE PATIENTS
Meth-OD:IXT-M200 在甲基苯丙胺过量患者中的 2A 期研究
  • 批准号:
    10425428
  • 财政年份:
    2020
  • 资助金额:
    $ 128.75万
  • 项目类别:
Optimization and testing of anti-methamphetamine antibody therapy to support pivotal clinical trials and commercialization
抗甲基苯丙胺抗体疗法的优化和测试以支持关键的临床试验和商业化
  • 批准号:
    10152573
  • 财政年份:
    2020
  • 资助金额:
    $ 128.75万
  • 项目类别:
Meth-OD: A PHASE 2A STUDY OF IXT-M200 IN METHAMPHETAMINE OVERDOSE PATIENTS
Meth-OD:IXT-M200 在甲基苯丙胺过量患者中的 2A 期研究
  • 批准号:
    10269933
  • 财政年份:
    2020
  • 资助金额:
    $ 128.75万
  • 项目类别:
STAMPOUT: A Phase 2a Study of Antibody for Methamphetamine Outpatient Therapy
STAMPOUT:甲基苯丙胺门诊治疗抗体的 2a 期研究
  • 批准号:
    9762072
  • 财政年份:
    2017
  • 资助金额:
    $ 128.75万
  • 项目类别:
Transition to Human Phase 1b Trials: Nonclinical Studies of an Anti-METH mAb
过渡到人体 1b 期试验:抗 METH 单克隆抗体的非临床研究
  • 批准号:
    9398663
  • 财政年份:
    2017
  • 资助金额:
    $ 128.75万
  • 项目类别:
STAMPOUT: A Phase 2a Study of Antibody for Methamphetamine Outpatient Therapy
STAMPOUT:甲基苯丙胺门诊治疗抗体的 2a 期研究
  • 批准号:
    9458985
  • 财政年份:
    2017
  • 资助金额:
    $ 128.75万
  • 项目类别:
Transition to Human Phase 1b Trials: Nonclinical Studies of an Anti-METH mAb
过渡到人体 1b 期试验:抗 METH 单克隆抗体的非临床研究
  • 批准号:
    9115554
  • 财政年份:
    2014
  • 资助金额:
    $ 128.75万
  • 项目类别:
Transition to Human Phase 1b Trials: Nonclinical Studies of an Anti-METH mAb
过渡到人体 1b 期试验:抗 METH 单克隆抗体的非临床研究
  • 批准号:
    8926379
  • 财政年份:
    2014
  • 资助金额:
    $ 128.75万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 128.75万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 128.75万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 128.75万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 128.75万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 128.75万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 128.75万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 128.75万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 128.75万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 128.75万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 128.75万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了